Skip to main content

Table 7 Persistence at 1 month, 6 months and 1 year in male LUTS (including OAB) sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

  N 1 month % [95% CI] 6 months % [95% CI] 1 year % [95% CI] Median (months) [95% CI]
All 12,383 72.9 34.8 25.2 2.5
   [72.1, 73.6] [33.9, 35.6] [24.4, 26.0] [2.4, 2.7]
Number of patients still at riska   9024 4304 3105  
Monotherapy 7946 65.6 37.6 27.7 2.5
   [64.5, 66.6] [36.5, 38.6] [26.8, 28.7] [2.3, 2.7]
Number of patients still at riska   5211 2986 2193  
Combination drug therapy 4437 85.9 29.7 20.6 2.5
   [84.9, 86.9] [28.4, 31.1] [19.4, 21.8] [2.4, 2.7]
Number of patients still at riska   3813 1318 912  
Monotherapy      
Darifenacin 47 74.5 34.0 27.7 2.3
   [59.4, 84.6] [21.0, 47.5] [15.9, 40.8] [1.7, 5.4]
Number of patients still at riska   35 16 13  
Fesoterodine 285 67.4 41.8 28.1 3.8
   [61.6, 72.5] [36.0, 47.4] [23.0, 33.4] [2.7, 5.2]
Number of patients still at riska   192 119 80  
Flavoxate 49 59.2 26.5 20.4 1.8
   [44.2, 71.4] [15.2, 39.3] [10.5, 32.6] [1.0, 3.1]
Number of patients still at riska   29 13 9  
Mirabegron 503 79.5 53.1 40.9 6.7
   [75.7, 82.8] [48.6, 57.3] [36.6, 45.2] [5.2, 9.5]
Number of patients still at riska   400 267 204  
Oxybutynin 2613 59.6 33.5 25.1 1.8
   [57.7, 61.4] [31.7, 35.3] [23.5, 26.8] [1.7, 1.9]
Number of patients still at riska   1557 875 653  
Propiverine 18 55.6 27.8 22.2 1.4
   [30.5, 74.8] [10.1, 48.9] [6.9, 42.9] [0.9, 4.9]
Number of patients still at riska   10 5 4  
Solifenacin 2759 70.2 40.2 29.5 3.2
   [68.5, 71.9] [38.4, 42.1] [27.8, 31.2] [2.9, 3.6]
Number of patients still at riska   1938 1110 812  
Tolterodine 1445 61.2 33.7 24.8 1.8
   [58.6, 63.6] [31.3, 36.1] [22.6, 27.1] [1.8, 2.2]
Number of patients still at riska   884 487 355  
Trospium 227 73.1 41.4 27.8 3.4
   [66.9, 78.4] [35.0, 47.7] [22.1, 33.7] [2.2, 4.9]
Number of patients still at riska   166 94 63  
Combination drug therapy      
Alfuzosin + solifenacin 47 87.2 40.4 29.8 4.1
   [73.8, 94.1] [26.5, 53.9] [17.6, 43.0] [2.1, 6.9]
Number of patients still at riska   41 19 14  
Doxazosin + oxybutynin 95 87.4 18.9 NO 2
   [78.8, 92.6] [11.8, 27.4] [1.8, 2.3]
Number of patients still at riska   83 18 13  
Doxazosin + solifenacin 114 89.5 36.0 20.2 3.8
   [82.2, 93.9] [27.3, 44.7] [13.4, 28.0] [2.8, 4.7]
Number of patients still at riska   102 41 23  
Doxazosin + tolterodine 69 87.0 39.1 29.0 3.1
   [76.4, 93.0] [27.7, 50.4] [18.8, 39.9] [2.1, 6.4]
Number of patients still at riska   60 27 20  
Dutasteride + solifenacin + tamsulosin 79 89.9 27.8 21.5 2.4
   [80.8, 94.8] [18.5, 38.0] [13.3, 31.1] [2.1, 3.6]
Number of patients still at riska   71 22 17  
Fesoterodine + tamsulosin 83 85.5 28.9 NO 2.6
   [75.9, 91.5] [19.6, 38.9] [2.1, 3.3]
Number of patients still at riska   71 24 12  
Finasteride + oxybutynin 62 88.7 32.3 17.7 2.5
   [77.8, 94.5] [21.1, 43.9] [9.5, 28.1] [1.8, 3.6]
Number of patients still at riska   55 20 11  
Finasteride + oxybutynin + tamsulosin 111 91.0 30.6 19.8 2.3
   [83.9, 95.0] [22.3, 39.3] [13.0, 27.7] [2.0, 3.6]
Number of patients still at riska   101 34 22  
Finasteride + solifenacin 96 90.6 44.8 32.3 3.9
   [82.8, 95.0] [34.7, 54.4] [23.2, 41.7] [2.1, 6.9]
Number of patients still at riska   87 43 31  
Finasteride + solifenacin + tamsulosin 233 91.0 45.1 28.8 4
   [86.5, 94.0] [38.6, 51.3] [23.1, 34.7] [3.4, 6.2]
Number of patients still at riska   212 105 67  
Finasteride + tamsulosin + tolterodine 57 96.5 40.4 28.1 3.9
   [86.7, 99.1] [27.7, 52.7] [17.2, 40.0] [2.8, 6.7]
Number of patients still at riska   55 23 15  
Finasteride + tolterodine 41 85.4 29.3 22.0 1.7
   [70.3, 93.1] [16.4, 43.4] [10.9, 35.5] [1.5, 3.9]
Number of patients still at riska   35 12 9  
Mirabegron + solifenacin 95 85.3 NO NO 2
   [76.4, 91.0] [1.7, 2.5]
Number of patients still at riska   81 11 6  
Mirabegron + tamsulosin 96 82.3 37.5 29.2 3.2
   [73.1, 88.6] [27.9, 47.1] [20.5, 38.4] [2.2, 4.7]
Number of patients still at riska   79 36 28  
Oxybutynin + solifenacin 102 84.3 NO NO 1.8
   [75.7, 90.1] [1.6, 1.9]
Number of patients still at riska   86 4 2  
Oxybutynin + tamsulosin 364 82.4 26.9 16.5 2.1
   [78.1, 86.0] [22.5, 31.6] [12.9, 20.5] [2.0, 2.3]
Number of patients still at riska   300 98 60  
Solifenacin + tamsulosin 902 86.7 39.9 29.4 3.6
   [84.3, 88.7] [36.7, 43.1] [26.4, 32.4] [3.2, 4.1]
Number of patients still at riska   782 360 264  
Solifenacin + tolterodine 114 77.2 NO NO 1.6
   [68.3, 83.9] [1.5, 1.8]
Number of patients still at riska   88 6 2  
Tamsulosin + tolterodine 248 82.3 33.5 24.2 3.3
   [76.9, 86.5] [27.7, 39.4] [19.1, 29.7] [2.6, 4.0]
Number of patients still at riska   204 83 60  
Tamsulosin + trospium 65 90.8 41.5 29.2 4.7
   [80.6, 95.7] [29.5, 53.1] [18.8, 40.5] [2.9, 7.1]
Number of patients still at riska   59 27 19  
Other combinations 1364 85.1 22.4 15.9 2.1
   [83.1, 86.9] [20.2, 24.6] [14.0, 17.9] [2.0, 2.2]
Number of patients still at riska   1161 305 217  
  1. Not Observable indicates that the number of patients still at risk was below the 20% of the initial sample threshold required to calculate persistence, or the median was not reached
  2. CI: confidence interval; LUTS: lower urinary tract symptoms; NO: not observable; OAB: overactive bladder aNumber of patients still observable at a given time and for whom no events occurred